1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Motherisk Update 2014
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting,
Details to be announced
- Read more in our News Archive
Current Studies at Motherisk
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
The Cancer in Pregnancy ForumArchived Questions and Answers
This Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
I would like to know if there is any risk of breastfeeding a newborn whose mother received Oxaliplatin 130 mg/m2 about 5 weeks before the cesarean and finished a cycle of Capecitabine (2.000 mg/m2 D1 to D14) 3 weeks before. Thank you very much
Oxaliplatin is a platinum compound similar to cisplatin. Oxaliplatin is extensively bound in peripheral tissues, which accounts for its long half-life. While breast milk levels are unavailable, but are probably low, breastfeeding is not advisable for many days (>20-30) and should be discontinued until milk platinum levels can be measured.
In cisplatin studies, excretion of platinum into milk was observed in 2 of the 3 cases reported, with the 3rd reporting no breast milk levels. The exact form and toxicity of platinum excreted into breastmilk is not known. The nursing infant would receive any platinum compounds orally rather than intravenously and oral absorption of oral platinum compounds by infants is not known.
- Breastmilk levels should be tested for platinum and not used as long as they are measurable
- Interruption of breastfeeding for >20-30 days
Capecitabine is converted to the active drug 5-fluorouracil (5-FU). It is readily absorbed orally and rapidly metabolized in most tissues to 5-FU in about 2 hours following administration. No intact fluorouracil can be detected in the plasma three hours after an IV injection. No data are available on the transfer of 5-FU to human milk. Mothers receiving injected 5-FU should withhold breastfeeding for a minimum of 24 hours after exposure.
Because platinum is not absorbed orally, and due to the time that has elapsed, there is no reason not to breastfeed in this case.